ArticleStem cell research & therapy2025
Mesenchymal stem cells undergoing apoptosis recover cyclophosphamide-induced cleft palate through modulation of NLR signaling mediated pyroptosis.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCleft palate is a common developmental disorder in craniofacial region, which cause the severe postnatal oral dysfunction. Mesenchymal stem cell (MSC) therapy has been revealed as a promising therapeutic approach in fetal developmental defects. However, since placental barrier blocks the transfer of cells from maternal circulation, how the MSC exert therapeutic effects and biological function to repair developmental injuries and maintain tissue homeostasis remains elusive.
methodsCyclophosphamide (CP)-induced cleft palate mice were used with replenishment of adipose-derived MSC (ADSC) or apoptotic vesicles (apoVs) derived from MSC, which of cleft palate were characterized by morphological analysis. PKH26 labeling and TUNEL assay were used in tracing of MSC or MSC-derived apoVs. Mechanistical studies were assessed by combinations of RNA-seq analysis, proteomic re-analysis and immunoassay.
resultsExogenous MSC recovered the CP-induced cleft palate in E14.5 and E16.5 fetuses. Intriguingly, we unexpectedly found that MSC decreased rapidly and underwent apoptosis in maternal placenta. Accordingly, we assumed MSC-derived apoVs were the mediator of MSC exerting therapeutic effects. MSC-derived apoVs were injected into the pregnant mice and remarkedly improved CP-induced cleft palate, which were traced in fetal multiple organs, particularly in palatine shelves. Mechanistically, transcriptomic and proteomic analysis revealed that MSC-derived apoVs suppressed NLR signaling associated gene expression. Subsequent experimental validation confirmed that MSC-derived apoVs inhibited NLRP3-Caspase-1 mediated pyroptosis in palatal tissues, thereby contributing to the rescue of cleft palate phenotype.
conclusionsOur studies revealed exogenous MSC underwent apoptosis and released apoVs to repair fetal cleft palate defects, which mechanistically reduced the NLR signaling mediated pyroptosis in palatal shelves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.